China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Accumulated Expenses of $3.3 million for Q1 2026, up 12.49% year-over-year from $2.9 million in Q1 2025, and up 1.17% quarter-over-quarter from $3.3 million in Q3 2025.
China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 12.49% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 12.49% YoY), while the FY2026 annual figure was $3.3 million, up 12.49% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $3.3 million, up from $3.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $3.5 million in Q1 2022, with the low at $2.8 million in Q1 2024.
- The 5-year median for Accumulated Expenses is $3.2 million (2023), against an average of $3.2 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses increased 15.84% in 2022, then slipped 11.89% in 2024.
- China SXT Pharmaceuticals' Accumulated Expenses stood at $3.3 million in 2022, then slipped by 0.89% to $3.2 million in 2023, then retreated by 10.05% to $2.9 million in 2024, then rose by 11.77% to $3.3 million in 2025, then grew by 1.17% to $3.3 million in 2026.
- Business Quant data shows SXTC's Accumulated Expenses at $3.3 million in Q1 2026, $3.3 million in Q3 2025, and $2.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | China SXT Pharmaceuticals | 32,029.92 | -28.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.30 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Sep 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 3.14 Mn |
| Sep 30, 2022 | 3.28 Mn |
| Mar 31, 2022 | 3.53 Mn |
| Sep 30, 2021 | 3.36 Mn |
| Mar 31, 2021 | 3.05 Mn |
| Sep 30, 2020 | 2.46 Mn |
| Mar 31, 2020 | 2.24 Mn |
| Sep 30, 2019 | 701,876.00 |
| Mar 31, 2019 | 691,522.00 |
| Sep 30, 2018 | 314,371.00 |
| Mar 31, 2018 | 416,226.00 |